BioPharmSignal logoBioPharmSignal

Biotech News

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics (AQST)Aquestive TherapeuticsEarnings

Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026 Continues pre-launch medical affairs activities and payer engagement On track to begin ex-U.S.

Related news

AQSTAquestive Therapeutics2026-07-29 11:00 EST

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

AQSTAquestive Therapeutics2026-05-13 20:01 EST

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

View all latest news

Aquestive Therapeutics

Oral Film Drug Delivery Company Aquestive Therapeutics develops medicines using proprietary film-based delivery technologies for allergic reactions and other conditions. Anaphylm Anaphylm is a postage-stamp-sized sublingual film containing a prodrug of epinephrine for severe allergic reactions, including anaphylaxis. It dissolves without...

Recent company news

AQSTAquestive Therapeutics2026-08-11 20:01 EST

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

AQSTAquestive Therapeutics2026-08-10 11:00 EST

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

AQSTAquestive Therapeutics2026-07-29 11:00 EST

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

AQSTAquestive Therapeutics2026-07-07 11:00 EST

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

AQSTAquestive Therapeutics2026-05-13 20:01 EST

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
4.29 USD
Market cap
493.02M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States